CESSATECH A/S DK -20 (8GN) - Net Assets
Based on the latest financial reports, CESSATECH A/S DK -20 (8GN) has net assets worth €12.16 Million EUR (≈ $14.21 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.39 Million ≈ $15.65 Million USD) and total liabilities (€1.23 Million ≈ $1.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 8GN liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €12.16 Million |
| % of Total Assets | 90.79% |
| Annual Growth Rate | -17.5% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 64.07 |
CESSATECH A/S DK -20 - Net Assets Trend (2021–2025)
This chart illustrates how CESSATECH A/S DK -20's net assets have evolved over time, based on quarterly financial data. Also explore total assets of CESSATECH A/S DK -20 for the complete picture of this company's asset base.
Annual Net Assets for CESSATECH A/S DK -20 (2021–2025)
The table below shows the annual net assets of CESSATECH A/S DK -20 from 2021 to 2025. For live valuation and market cap data, see CESSATECH A/S DK -20 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €12.16 Million ≈ $14.21 Million |
+46.92% |
| 2024-12-31 | €8.27 Million ≈ $9.67 Million |
+531.16% |
| 2023-12-31 | €-1.92 Million ≈ $-2.24 Million |
-108.04% |
| 2022-12-31 | €23.86 Million ≈ $27.89 Million |
-9.10% |
| 2021-12-31 | €26.24 Million ≈ $30.68 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CESSATECH A/S DK -20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 66.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €8.44 Million | 69.44% |
| Other Components | €3.71 Million | 30.56% |
| Total Equity | €12.16 Million | 100.00% |
CESSATECH A/S DK -20 Competitors by Market Cap
The table below lists competitors of CESSATECH A/S DK -20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Respiri Ltd
AU:RSH
|
$39.01 Million |
|
Daewoo Elec Co
KO:009320
|
$39.02 Million |
|
TradeDoubler AB
ST:TRAD
|
$39.03 Million |
|
Watos Corea Co. Ltd
KQ:079000
|
$39.03 Million |
|
Live Ventures Inc
NASDAQ:LIVE
|
$39.01 Million |
|
HyosungONBCo.Ltd
KQ:097870
|
$39.01 Million |
|
Kworld Computer Co Ltd
TWO:3287
|
$39.00 Million |
|
Integrated Research Ltd
AU:IRI
|
$38.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CESSATECH A/S DK -20's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,274,000 to 12,156,000, a change of 3,882,000 (46.9%).
- Net loss of 10,904,000 reduced equity.
- New share issuances of 14,645,000 increased equity.
- Other factors increased equity by 141,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.90 Million | -89.7% |
| Share Issuances | €14.64 Million | +120.48% |
| Other Changes | €141.00K | +1.16% |
| Total Change | €- | 46.92% |
Book Value vs Market Value Analysis
This analysis compares CESSATECH A/S DK -20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.50x to 3.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.29 | €2.15 | x |
| 2022-12-31 | €1.73 | €2.15 | x |
| 2023-12-31 | €-0.14 | €2.15 | x |
| 2024-12-31 | €0.47 | €2.15 | x |
| 2025-12-31 | €0.65 | €2.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CESSATECH A/S DK -20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -190.70%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.10x
- Recent ROE (-89.70%) is below the historical average (-74.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -44.09% | 0.00% | 0.00x | 1.17x | €-14.19 Million |
| 2022 | -61.44% | 0.00% | 0.00x | 1.18x | €-17.04 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-26.34 Million |
| 2024 | -177.30% | -590.10% | 0.16x | 1.92x | €-15.50 Million |
| 2025 | -89.70% | -190.70% | 0.43x | 1.10x | €-12.12 Million |
Industry Comparison
This section compares CESSATECH A/S DK -20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CESSATECH A/S DK -20 (8GN) | €12.16 Million | -44.09% | 0.10x | $39.01 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-c… Read more